Idera Reports Positive Results from Psoriasis Study

March 28, 2014 12:08 PM

12 0

Idera Pharmaceuticals Inc. (IDRA) said a recent clinical study of its plaque psoriasis treatment met its objectives, allowing the company to push forward with the treatment's development.

The Phase 2 trial of IMO-8400, Idera's lead clinical candidate, involved 32 patients with moderate to severe plaque psoriasis, a condition affecting the skin.

Read more

To category page